Search the Newsreel

Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed?

Halozyme Therapeutics reported record second-quarter results with revenue up to US$481 million and net income of US$229.91 million, leading to increased full-year 2026 revenue guidance. The company also accelerated share buybacks and secured new ENHANZE collaborations, reinforcing its royalty-led business model. While these achievements …

Haleon plc (LON:HLN) Passed Our Checks, And It's About To Pay A UK£0.024 Dividend

Shalfa Facilities Management Logs Surge in H1 Net Profit; Revenue Up

Income Investors Should Know That Halfords Group plc (LON:HFD) Goes Ex-Dividend Soon

Price to earnings forward of Schiehallion Fund Limited Accum Ordinary- USD – LSE:MNTN

This nuclear startup and Halliburton repurposed oil-drilling tech in a bid to solve America’s radioactive waste problem

If you drive to the middle of nowhere in central Texas near Cameron—population 5,300—and down a gravel road, you'll come upon a security gate with a sign stating, "Watch out for the cows." The warning is no hyperbole, as cattle block the road, delaying …

Eshallgo Inc Grants 425,000 Class A Shares Under 2026 Incentive Plan

Eshallgo Inc issued 425,000 Class A shares on August 5, 2026, to employees and a consultant under its 2026 Share Incentive Plan. This action is intended to compensate them for continued service and align their interests with shareholders. While it introduces modest dilution for …

HALLADOR ENERGY Q2 2026 Earnings Preview: Recent $HNRG Insider Trading, Hedge Fund Activity, and More

Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price

Halozyme Therapeutics (HALO) has seen a 106.2% return over five years, but its current valuation suggests the stock is expensive, trading at 29.2x earnings compared to a fair P/E of 20.1x. Despite strong financial results and collaboration agreements, the company's P/E ratio is above …

Free float of Hall Chadwick Acquisition Corp. – NASDAQ:HCACR

This article provides an overview of the free float for Hall Chadwick Acquisition Corp. (NASDAQ: HCACR). It appears to be a stub or data-focused page from TradingView, indicating no specific numerical data regarding the free float but setting the context for where such information …

Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks

Halozyme Therapeutics reported record second-quarter results with revenue at US$481 million and net income at US$229.91 million, leading to a 24.9% stock increase. The company raised its 2026 revenue guidance to US$1.84 billion - US$1.91 billion and boosted share buybacks by an additional US$175.01 …

Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Raised to $99.56, Implies 16% Upside

Analysts have raised the average 12-month price target for Halozyme Therapeutics, Inc. (HALO) stock to $99.56, up from $86.89. This new target suggests a potential upside of approximately 16% from its recent closing price. The consensus rating among 11 analysts remains a "Buy," with …

Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising …

Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs

Halozyme Therapeutics (HALO) stock rallied 20% after reporting strong Q2 2026 earnings, exceeding revenue and EPS expectations, driven by a 47.5% increase in total revenue and 39.2% increase in net income. The company also raised its full-year 2026 revenue and earnings guidance, reinforcing its …

Haleon PLC (HLN) Aktuelle Aktien-News

Robert Half International Inc (RHJ.DU) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed financial information for Robert Half International Inc (RHJ.DU), including its current stock price, dividend announcements, historical performance data, and key statistics. It shows the stock trading at 36.49 EUR, with a dividend of 0.59 EUR announced, and offers …

Halliburton Company $HAL Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in Halliburton Company (NYSE:HAL) by 80% in the first quarter, now owning 91,732 shares valued at approximately $3.58 million. Other institutional investors also significantly increased their stakes. Wall Street analysts maintain a "Moderate Buy" rating for HAL …

Robert Half (NYSE:RHI) Reaches New 52-Week High - Here's What Happened

Robert Half (NYSE:RHI) shares recently hit a new 52-week high of $43.94, trading significantly above its previous close. This surge occurred despite mixed analyst ratings, with some upgrading to "buy" and others maintaining "sell" recommendations. The company reported quarterly revenue of $1.34 billion and …

Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO

Assenagon Asset Management S.A. significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4,578.9% in the second quarter, now holding 997,643 shares valued at $78.1 million. This increase follows Halozyme's strong second-quarter results, which exceeded analyst expectations with adjusted EPS of $2.28 and …

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen

Halozyme Therapeutics (NASDAQ:HALO) was upgraded to a "strong-buy" rating by Wall Street Zen following impressive quarterly results where EPS and revenue significantly beat estimates. The company also raised its 2026 guidance, driven by strong royalty growth and new ENHANZE and Hypercon agreements. Despite some …

Haleon PLC (HLN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance. …

John Marshall Bancorp, Inc. Q2 2026: Revenue $29.7M, EPS $0.5— 10-Q Summary

John Marshall Bancorp, Inc. reported strong second-quarter 2026 results, with revenue reaching $29.7 million and diluted EPS at $0.50. This growth was fueled by increased loan yields, higher loan balances, and improved funding stability from deposit growth. The company also saw a significant increase …

Notícias das Ações da Robert Half Inc (RHI)

Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...

This article first appeared on GuruFocus. Total Revenue: Increased 48% year-over-year to $481 million. Royalty Revenue: Record growth of 50% year-over-year to $308 million. Adjusted EBITDA: Increased 46% to $328.8 million, with a margin of more than 65%. Net Income: Increased 39% to $229.9 …

Charter Hall Stock And 2 More Shares Linked To Retiree Spending

Charter Hall Retail REIT Earnings: Property Values Rise; Securities Undervalued

Haleon plc (HLN) Stock Price, News, Quote & History

This page provides a comprehensive overview of Haleon plc (HLN) stock, including its current price, dividend information, key financial metrics, and performance data. It details the company's business in consumer healthcare, offering products like oral care, vitamins, and pain relief, and compares its performance …

HALO Surges As Halozyme Hikes 2026 EPS And Revenue Outlook

John Marshall Bancorp Inc (JMSB) Stock News Today

This page provides current stock news for John Marshall Bancorp Inc (JMSB). It shows the stock price, market cap, P/E ratio, and states that more news, earnings, and analyst ratings will be updated soon. The article is a placeholder indicating future updates for JMSB's …

Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth. Continue Reading

Robert Half International stock hits 52-week high at 42.26 USD

Robert Half International (RHI) stock reached a 52-week high of $42.26, currently trading at $42.60, marking a significant 57% year-to-date surge and a 23.54% increase over the past year. InvestingPro analysis suggests the stock is undervalued, and the company offers a 5.8% dividend yield, …

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

John Marshall Bancorp (NASDAQ: JMSB) grows loans and boosts first-half earnings

John Marshall Bancorp (NASDAQ: JMSB) reported increased profitability for the second quarter and first six months of 2026, with net income rising to $7.019 million and $13.121 million respectively. This growth was driven by higher net interest income, increased loan balances, and improved yields …

Halliburton Co. stock underperforms Friday when compared to competitors

Halliburton Co. (HAL) stock underperformed on Friday, shedding 1.91% to $31.89, despite a positive trading session for the broader market with the S&P 500 and Dow Jones Industrial Average rising. The company's stock closed 26.84% below its 52-week high achieved in May.

Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike

Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new …